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Abstract
Background: The objectives of this pilot study were to evaluate treatment quality for the risk
factors of hypertension, diabetes and hyperlipidemia as well as the overall treatment quality for
patients on an internal nephrology ward. This evaluation included the collection of data concerning
the quality of therapeutic drug monitoring, drug use and potential drug-drug interactions.
Establishing such baseline information highlights areas that have a need for further therapeutic
intervention and creates a foundation for improving patient care, a subject that could be addressed
in future clinical pharmacy research projects.
Methods:  Medical charts of patients treated on a single internal nephrology ward were
retrospectively evaluated using a predefined data collection form. Assessment of further need for
therapeutic intervention was performed.
Results: For 76.5% (n = 78) of the total study population (n = 102), there was either a possibility
(39.2%, n = 40) or a need (37.3%, n = 38) for further intervention based on the overall assessment.
For the risk factors of hypertension, diabetes and hyperlipidemia, the proportions of patients that
require further intervention were 78.8% (n = 71), 90.6% (n = 58) and 87.9% (n = 58), respectively.
Patients with diabetes or hyperlipidemia were less likely to have optimal risk factor control. The
number of drugs prescribed and the number of potential drug-drug interactions were significantly
higher after in-hospital treatment.
Conclusion:  Risk factor treatment needs optimisation. Risk factor management, systematic
medication reviews, and screening for and management of potential drug-drug interactions deserve
great attention. Clinical pharmacy services could help in the achievement of treatment goals.
Background
Health-care professionals, such as physicians, nurses, and
(clinical) pharmacists, in both inpatient and outpatient
settings are increasingly confronted with a growing
number of patients with chronic kidney disease (CKD)
and end-stage renal disease (ESRD)[1]. Medical care for
CKD patients is complex due to widespread co-morbidi-
ties and major risk factors (RF) for CKD or cardiovascular
disease (CVD) [2,3]. The progression of CKD and the
deterioration of kidney function from stage 1 CKD [3] to
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more severe stages can be slowed by optimal treatment of
underlying co-morbidities and RFs, which can be accom-
plished with lifestyle modifications and/or different phar-
macological interventions that address the treatment of
hypertension, diabetes mellitus and hyperlipidemia,
among others. The slowing down of disease progression is
pivotal for prolonging the period before stage 5 CKD or
ESRD, which involves the necessary initiation of either
dialysis or evaluation of suitability for kidney transplanta-
tion. Several initiation and progression factors have been
shown to influence disease onset and progression [3,4].
Large-scale efforts that target these RFs have been initiated
to improve outcomes in the CKD population [5].
The involvement of clinical pharmacists as members of
the interdisciplinary patient care team responsible for the
management of many different diseases has proven to be
beneficial and has been associated with positive patient
outcomes [6-8]. Clinical pharmacists have also been influ-
ential in the field of nephrology and have provided valu-
able support for the achievement of defined goals in the
treatment of different RFs and management of drug-
related problems in the ESRD population [9-12].
This pilot study was performed to establish baseline data
that address (1) the quality of RF management, (2) overall
treatment quality, (3) quality of therapeutic drug moni-
toring (TDM), (4) quantitative drug use at admission and
discharge and (5) the frequency of potential drug-drug
interactions (pDDIs) in the studied patient population as
well as in the predefined subgroup of kidney transplant
patients (TX subgroup). The retrospective evaluation of
these parameters should identify areas with the need for
further intervention and possibilities for the improve-
ment of patient care that could be addressed in future clin-
ical pharmacy research.
Methods
Study design, group and setting
A retrospective review was conducted of 102 randomly
selected medical histories of patients receiving treatment
between August 2006 and April 2008 on an internal neph-
rology ward of General Hospital in Vienna. Data were col-
lected between January and May 2008. There were no
direct interventions performed on patients. This descrip-
tive study was approved by the local ethics committee of
the Medical University of Vienna and the Vienna General
Hospital.
Data sources and collection
Medical charts, physicians' admission and discharge let-
ters and cumulative laboratory findings were the only data
sources used. Data were collected according to a prede-
fined data collection form, which was divided into six cat-
egories: (1) sociodemographic criteria; (2) cause of
hospitalisation, further medical conditions (co-morbidi-
ties) and underlying renal disease; (3) treatment of the
predefined RFs of hypertension, diabetes mellitus and
hyperlipidemia in the total population and quality of
TDM in the TX subgroup; (4) drug regimen at the time of
admission and discharge; (5) number and severity of
pDDIs and (6) overall quality of RF treatment. Further-
more, glomerular filtration rates (GFRs) at discharge and
at admission were estimated using the Modification of
Diet in Renal Disease (MDRD) study equation. Stages of
CKD (based on GFR at discharge) were assigned according
to the National Kidney Foundation/Kidney Disease Out-
comes Quality Initiative (NKF/KDOQI) classification [3].
Assessment of RF treatment quality and overall assessment
Treatment quality during hospitalisation was assessed
according to established guidelines for each RF, for quality
of TDM in the TX subgroup and for overall treatment
quality (see Table 1). The quality of RF and TDM manage-
ment as well as overall treatment quality was assessed
numerically on a scale from one to four (see Table 2).
Patient treatment histories that were assessed as being a
two or three on this quality scale were compiled and cate-
gorised as patients for whom further therapeutic interven-
tion would have been either beneficial (2) or necessary
(3) and therefore would represent potential domains for
intervention by a clinical pharmacist.
Screening for pDDIs
Admission drug histories and discharge drug histories
were electronically screened for pDDIs using Medis®.
Table 1: Risk factor reference values
Risk factor Reference Values
Hypertension 23,34 Non-diabetic patients <140/90 mm/Hg
Diabetic patients <130/80 mm/Hg
Patients with diabetic nephropathy <125/75 mm/Hg
Diabetes mellitus 34 Fasting plasma blood glucose <110 mg/dl
Glycosylated haemoglobin HbA1c 4-6%
Hyperlipidemia 25 Low density cholesterol <130 mg/dl
Total cholesterol <200 mg/dl
Triglycerides <200 mg/dlBMC Clinical Pharmacology 2009, 9:15 http://www.biomedcentral.com/1472-6904/9/15
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pDDIs were classified into four categories of relevance
given by the database, namely severe, moderate, minor and
unknown relevance (see Appendix for detailed explana-
tions). Only pDDIs classified as severe and moderate were
included in the statistical analysis. Individual drug dos-
ages were not taken into account when assessing pDDIs.
Statistical analysis
Absolute and relative frequencies as well as 95% confi-
dence intervals (lower CI and upper CI) are reported for
the four categories of overall assessment for each RF and
for overall RF management. Statistical analyses were con-
ducted on the total study population and for the TX sub-
group. To analyse the influence of the RFs (hypertension,
diabetes mellitus and hyperlipidemia) on assessment cat-
egory, an ordinal logistic regression analysis of assessment
categories one, two or three (see Table 2) was calculated
(category 4 is omitted). The probability of the patient
being in a higher category was also modelled. P-values,
odds ratios and the corresponding 95% confidence inter-
Table 2: Categories for assessment of individual risk factors, therapeutic drug monitoring and overall assessment
Individual RFa and TDMb Assessment of overall treatment quality
Assessment Explanation Assessment Explanation
1 No need for intervention Valuesd according to references in more 
than 2/3 of available values; Values 
better at discharge than at admission; 
Disease/RFa is treated; no severe 
pDDIsc
Very good RFa management No improvements necessary
2 Improvement possible Valuesd outside of reference range in 
more than 1/3 of available values; Values 
worse at discharge; severe pDDIsc; RF is 
treated
Good RFa management Up to two individual RFsa being assessed 
as "improvement possible" (category 2); 
no untreated RFsa (category 3)
3 Disease untreated No drug therapy for RFa treatment; no 
TDM performed, although appropriate
Improvement in RFa 
management needed
More than two individual RFsa or 
TDMsb being assessed as "improvement 
possible" (category 2) or untreated RFa 
(category 3)
4 No conclusion possible Missing data; inconclusive data No conclusion possible Missing data; inconclusive data
a RF = risk factor
b TDM = therapeutic drug monitoring
c pDDI = potential drug-drug interaction
d e.g., blood pressure, fasting blood glucose, lipid levels, plasma levels of immunosuppressants
Table 3: Sociodemographic characteristics, stages of CKD and length of stay
Total population n = 102 TXa subgroup n = 49
n% n %
Men/Women 67/35 65.7/34.3 37/12 75.5/24.5
Age, years
Mean ± SDb 55.5 ± 13.4 55.4 ± 11.4
Range 24-86 29-73
BMIc, kg/m2
Mean ± SDb 26.3 ± 5.1 26 ± 4.8
Range 15-40.2 16-40.2
Stages of CKD n = 80 n = 44
2 3 3.8 2 2.3
33 9 4 8 . 8 3 2 7 2 . 7
41 5 1 8 . 8 7 1 5 . 9
52 3 2 8 . 8 3 6 . 8
Length of stay, days
Mean ± SDb 14.8 ± 10.5 17.06 ± 9.9
Range 2-47 2-41
a TX = transplantation
b SD = standard deviation
c BMI = body mass indexBMC Clinical Pharmacology 2009, 9:15 http://www.biomedcentral.com/1472-6904/9/15
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vals are given. For the analysis, the RFs of diabetes and
hyperlipidemia were both classified into "no diabetes
mellitus" or "no hyperlipidemia" versus "diabetes melli-
tus" or "hyperlipidemia". The analysis was performed
using SAS 9. Means will be presented as mean (range,
standard deviation).
Results
Sociodemographic and patient characteristics
Sociodemographic characteristics and stages of CKD for
the total study population and TX subgroup are shown in
Table 3. Major causes of hospitalisation in the study pop-
ulation and the underlying renal diseases are shown in
Figures 1 and 2, respectively.
RF: hypertension
A diagnosis of hypertension was seen in 88.2% (90) of
patients. The absolute and relative frequencies as well as
the corresponding confidence intervals for hypertension
are given in Table 4 for the four different categories of
overall assessment of the total study population. In 78.8%
(71) of patient cases, there was a possibility or need for
further therapeutic interventions. Hypertensive patients
were treated on the ward for a mean time of 15.2 days (d)
(range 2-47, standard deviation 10.84), with an average of
7.7 d (0-45, 9.87) of blood pressure values out of the indi-
vidual reference range. Estimation of renal function at
admission and discharge showed a mean GFR of 23.1 and
30.1 mL/min/1.73 m2, respectively. Stages 2 to 5 CKD
were present in 4.1, 50.7, 17.8 and 27.4% of hypertensive
patients, respectively.
RF: diabetes mellitus and elevated fasting blood glucose
A total of 62.8% (64) of patients in this RF group had
either a definitive diagnosis of diabetes (diabetes mellitus
type I (3.9%, n = 4) or diabetes mellitus type II (30.39%,
n = 31)) or continuously elevated fasting blood glucose
(FBG) out of reference range (28.4%, n = 29). Absolute
and relative frequencies as well as corresponding confi-
dence intervals for the four different categories of overall
assessment for the total study population are given in
Table 4. The majority (90.6%, 58) of patients had a need
for further therapeutic intervention. Patients with diabetes
mellitus type I were treated on the ward for an average of
11.3 d (4-22, 8.14), with FBG levels out of reference range
on 5.5 d (1-10, 4.65). Patients with diabetes mellitus type
II were treated for an average of 30.0 d (2-45, 11.9), with
FBG levels out of reference on 6.9 d (1-24, 6.36). Patients
with continuously elevated FBG levels were treated for
16.4 d (2-39, 9.89), with elevated FBG for 6.7 d (2-19,
4.6) on average. Glycosylated haemoglobin (HbA1c) lev-
els were evaluated and analysed as a marker of long-term
treatment quality. In 43.8% (n = 28) of patients in the dia-
betes RF group, there was no information available about
HbA1c  values. In 25% (n = 16) of patients, reported
HbA1c levels were in accordance with the reference range
(see Table 1), and in 25% (n = 16) of patients HbA1c levels
were outside of the reference range. Of patients with
HbA1cvalues outside of the reference range, 68.8% (n =
11) had diabetes type II. Estimation of renal function at
admission and discharge showed a mean GFR of 23.2 and
30.2 mL/min/1.73 m2, respectively. Stages 2 to 5 CKD
were present in 3.9, 49.0, 21.6 and 25.5% of patients with
the RF of diabetes, respectively.
Major causes of hospitalization, classified Figure 1
Major causes of hospitalization, classified. TX trans-
plantation. ADE adverse drug event.
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Underlying nephrologic disease (where available). 
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RF: Hyperlipidemia
Of the patients reviewed, 64.7% (n = 66) were diagnosed
with hyperlipidemia, while 41.2% (n = 42) showed con-
tinuously elevated cholesterol-levels and 5.9% (n = 6)
showed elevated triglyceride-levels. HMG-Co-enzyme-A-
inhibitors (statins) were used in 17.7% (18) of patients
for cardiovascular event prophylaxis. Absolute and rela-
tive frequencies as well as corresponding confidence inter-
vals of the hyperlipidemia RFs for the four different
categories of overall assessment for the total study popu-
lation are given in Table 4. A possible need for further
therapeutic intervention was found in 87.9% (58) of the
patients in the study. Estimation of renal function at
admission and discharge showed a mean GFR of 21.7 and
28.4 mL/min/1.73 m2, respectively. Stages 2 to 5 CKD
were present in 1.9, 49.1, 20.8 and 28.3% of patients with
the RF of hyperlipidemia, respectively.
Characteristics and quality of TDM
The plasma drug levels of immunosuppressant medica-
tions were determined and the dosages were adjusted in
89.8% (44) of the TX subgroup patients. Immunosup-
pressive medications primarily consisted of a three-way
combination of calcineurin inhibitors (tacrolimus
(79.6%, 35) or ciclosporin (20.5%, 8)), anti-metabolites
(mycophenolate mofetil (70.5%, 35), mycophenolic acid
(18.2%, 8) or azathioprine (4.5%, 2)) and corticosteroids.
In 25% (11) of the TX subgroup patients, a switch in
immunosuppressant medication was necessary due to
adverse drug events (ADEs). For example, tacrolimus
induced tremors and mycophenolate mofetil induced
diarrhoea. The quality of TDM was only assessable if a
defined therapeutic range was available in the medical
chart (61.4%, 27). The number of days with sub-thera-
peutic and supra-therapeutic concentrations was evalu-
ated based on these defined ranges. Absolute and relative
frequencies of TDM for the four different categories of
overall assessment in the TX subgroup are given in Table
4.
Overall assessment of treatment quality
Absolute and relative frequencies and corresponding con-
fidence intervals for overall assessment of treatment qual-
ity in the total study population and TX subgroup are
shown in Table 5. A need for further optimisation of RF
treatment was observed in 76.5% (78) of the total study
population and 81.6% (40) of the TX subgroup.
Influence of individual RFs on overall treatment quality
Regression analysis showed that the diabetes mellitus and
hyperlipidemia RFs had a significant impact on assess-
ment outcome. Patients with diabetes (p = 0.001, OR
4.309, 95%CI: 1.81-10.25) or hyperlipidemia (p =
0.0085, OR 3.146, 95%CI: 1.34-7.39) had a higher overall
Table 4: Assessment of individual risk factors and quality of therapeutic drug monitoring
No need for intervention Improvement possible Disease untreated/
No TDMa
No conclusion possible
% (n) 95% CIb % (n) 95% CIb % (n) 95% CIb % (n) 95% CIb
Hypertension
n = 90
17.8 (16) 0.10-0.26 37.8 (34) 0.28-0.48 41.1 (37) 0.31-0.51 3.3 (3) 0.00-0.07
Diabetes mellitus
n = 64
7.8 (5) 0.01-0.14 42.2 (27) 0.30-0.54 48.4 (31) 0.36-0.61 1.6 (1) 0.00-0.05
Hyperlipidemia
n = 66
9.1 (6) 0.02-0.16 42.4 (28) 0.31-0.54 45.5 (30) 0.33-0.57 3.0 (2) 0.00-0.07
TDMa
n = 44
29.6 (13) 0.17-0.45 34.1 (15) 0.20-0.50 0.0 (0) - 36.4 (16) 0.22-0.52
For explanations of assessment categories see table 2.
a TDM = therapeutic drug monitoring
b CI = confidence interval
Table 5: Overall assessment of treatment quality
Very good RFa management Good RFa management Improvement needed No conclusion possible
% (n) 95% CIb % (n) 95% CIb % (n) 95% CIb % (n) 95% CIb
Total n = 102 19.6 (20) 0.12-0.27 39.2 (40) 0.30-0.49 37.3 (38) 0.28-0.47 3.9 (4) 0.00-0.08
TXc subgroup
n = 49
16.3 (8) 0.06-0.27 32.7 (16) 0.20-0.46 49.0 (24) 0.35-0.63 2.0 (1) 0.00-0.06
For explanations of assessment categories see table 2.
a RF = risk factor
b CI = confidence interval
c TX = transplantationBMC Clinical Pharmacology 2009, 9:15 http://www.biomedcentral.com/1472-6904/9/15
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risk of being assessed in category 2 (good risk factor man-
agement, but improvement possible) or category 3 (improve-
ment needed). This correlation was not shown for the
hypertension RF (p = 0.2704, OR 2.056, 95%CI: 0.57-
7.40).
Quantitative drug use and pDDIs in the total study 
population
The total sum of prescribed drugs in the total study popu-
lation was 1110 at admission and 1220 at discharge. Table
6 shows the number of drugs prescribed, number of
pDDIs and number of pDDIs per drug prescribed.
All three parameters showed significantly higher values at
discharge compared to admission. Treatment on the ward
was significantly associated with an elevated number of
drugs prescribed and an elevated number of pDDIs.
In the total study population, 45.1% (46) of patients had
an increase in the number of pDDIs during treatment on
the ward, 41.2% (42) had no change in the number of
pDDIs and 13.7% (14) had a decrease in the number of
pDDIs. In 43.2% (44) of all evaluated patients, at least
one pDDI was associated with an increased probability
for nephrotoxicity, thus increasing the risk of acute renal
failure and aggravation of renal function.
Quantitative drug use and pDDIs in the TX subgroup
The sum of drugs prescribed to the TX subgroup patients
was 619 at admission, compared with 650 at time of dis-
charge. The number of drugs prescribed, number of
pDDIs and number of pDDIs per drug prescribed are
shown in Table 6.
In-hospital treatment was associated with a significantly
elevated number of pDDIs per patient and pDDIs per
drug prescribed. When the number of drugs prescribed
per patient was compared, there was no statistically signif-
icant difference. In 44.9% (22) of the TX subgroup
patients, the number of pDDIs increased during treatment
on the ward, 38.8% (19) of patients had no change in the
number of pDDIs and 16.3% (8) of patients had a
decreased incidence of pDDIs during treatment on the
ward. In 83.7% (41) of evaluated patients, at least one
pDDI was associated with an increased probability of
nephrotoxicity, which increased those patients' risk of
developing acute renal failure and having an aggravation
of renal function.
Discussion
The study results show that the management of the indi-
vidual RFs of hypertension, diabetes and hyperlipidemia
requires improvement. In the overall assessment of treat-
ment quality, more than three-quarters of the patients
showed a possibility or evident need for further interven-
tion to reach the treatment goals. Very good RF manage-
ment was evident in less than 20% of patients for each of
the investigated RFs. For diabetes and hyperlipidemia, this
proportion was even under the 10% threshold. Based on
regression analysis, patients with diabetes or hyperlipi-
demia were four and three times less likely, respectively,
to have optimal RF control. Our results are consistent with
published studies and reviews that address treatment
quality and adherence to treatment guidelines for hyper-
tension [13-19], diabetes mellitus [15,20,21] and hyperl-
ipidemia [15,19] in CKD patients.
The apparent need for improvement in RF control in our
study population must be discussed in light of the special
features of the nephrological patient population.
Hypertension, either as a cause or a complication of CKD,
is prevalent in up to 75% of patients with CKD stage 3-5,
in up to 80% of kidney transplant patients and in up to
Table 6: Quantitative drug use and potential drug-drug interactions at hospital admission and discharge
Admission Discharge
Total study population n = 102 Mean ± SDa Range Mean ± SDa Range P-valueb
Number of drugs per patient 10.9 ± 4.2 0-20 12.1 ± 4.3 2-21 <0.0001*
Number of pDDIsc per patient 1.9 ± 1.9 0-8 2.7 ± 2.5 0-11 <0.0001*
Number of pDDIsc per drug prescribed 0.2 ± 0.2 0-0.83 0.2 ± 0.2 0-0.64 0.0016*
TXd subgroup n = 49
Number of drugs per patient 12.6 ± 3.1 4-20 13.3 ± 3.2 5-20 0.055
Number of pDDIsc per patient 1.8 ± 2.4 0-8 2.7 ± 2.8 0-11 0.014*
Number of pDDIsc per drug prescribed 0.1 ± 0.1 0-0.53 0.2 ± 0.2 0-0,64 0.014*
Only pDDIs classified as moderate or severe were included in the analysis.
a SD = standard deviation
b p = statistical significance according to the t-test
c pDDIs = potential drug-drug interactions
d TX = transplantation
* Statistically significantBMC Clinical Pharmacology 2009, 9:15 http://www.biomedcentral.com/1472-6904/9/15
Page 7 of 9
(page number not for citation purposes)
90% of maintenance haemodialysis patients [22,23]. Vir-
tually all patients in the study population had kidney
function of CKD stage 3 or worse, nearly 50% had one or
more kidney transplantations performed, and 27% were
dependent on renal replacement therapy (e.g., haemo- or
peritoneal dialysis). The very high prevalence and the
multifactorial pathogenesis of hypertension in renal dis-
ease (e.g., sodium retention and fluid overload and struc-
tural kidney changes) and the steady decline in renal
function make it difficult per se to reach tight treatment
goals. Antihypertensive polypharmacotherapy was there-
fore almost necessary in our study population to even
approximate treatment goals. Our study findings stress
the importance of drawing attention to tight blood pres-
sure control, as in about the half of the treatment period,
blood pressure control was suboptimal. Second, control
of diabetes and hyperlipidemia management was also
suboptimal. The relevance of these findings is emphasised
by the fact that diabetes is not only the leading cause of
CKD in developed countries [24], but diabetes and hyper-
lipidemia are also two of the most important RFs for car-
diovascular disease. Of note, CKD patients represent a
priori the highest risk group for CVD [3]. Therefore, guide-
lines [24,25] recommend strict glycemic and lipidemic
control. Besides patients with a confirmed diagnosis of
diabetes mellitus, we also included patients with continu-
ously elevated FBG in the diabetes RF group. Continu-
ously elevated FBG represents, in itself, a RF for the
development of diabetes mellitus II, and therefore, clarifi-
cation and management deserves attention. One fourth of
patients in the diabetes RF group had glycosylated haemo-
globin values outside of the reference range, confirming
the need for improvement of long-term glycemic control,
especially for diabetes mellitus II where around 68% of
patients had HbA1c levels outside of the reference range.
In nearly 50% of patients in the diabetic subgroup, glyco-
sylated haemoglobin values were totally lacking, and
therefore, no information was available concerning the
long-term control of their diabetes. Furthermore, the pro-
portion of untreated hyperlipidemia of around 45% also
stresses the need for intervention and improvement.
Nearly half of our study population was kidney transplant
patients. Thus, concomitant immunosuppressive therapy
may have also negatively biased RF control, as hyperten-
sion, diabetes and hyperlipidemia are all well-described
side effects of calcineurin inhibitors. However, our study
was not designed to assess a potential correlation. Finally,
the main focus during hospitalisation often lies in curing
acute disease and in necessary treatment, and conse-
quently, optimisation of RF treatment often takes a back
seat. Simple negligence and unintended oversight may
also be considered as reasons for suboptimal RF control.
In summary, there seems to be vast room for improve-
ment in the control of the investigated RFs in our study
population. Clinical pharmacists' activities have proved
beneficial for the achievement of treatment goals [10-12].
Our study also examined the quality of TDM in patients
receiving immunosuppressants. For the quality analysis,
the number of TDM drug levels outside of the reference
range was used as a surrogate parameter. For approxi-
mately 40% of patients, written information regarding the
desired drug concentration range, depending on time
since transplantation, was missing in the medical charts
and therefore could not be assessed. It was found that
only approximately one third of patients with kidney
transplants were without need of further intervention.
This assessment emphasises the fact that immunosuppres-
sant dose adjustments are common and optimal dosing
regimens are difficult to determine, especially in the early
postoperative phase [26,27]. Furthermore, frequent med-
ication changes, namely drug additions and discontinua-
tions, complicate dosing regimen optimisation. Widely-
used immunosuppressives have great inter- and intra-
individual pharmacokinetic variability and many con-
founding factors (e.g., race, time since transplantation, sex
and metabolic profile) that have to be taken into account
when adapting dosages on the basis of plasma drug con-
centration [28]. Constant plasma drug levels correspond-
ing to time since transplantation should be the goal. ADEs
are also common in the kidney transplant patient popula-
tion. Common ADEs seen with immunosuppressives are
as follows: new-onset diabetes mellitus, tremors (tac-
rolimus), hyperlipidemia, hypertension, hypertrichosis
(ciclosporin), and gastrointestinal side effects, such as
diarrhoea (mycophenolate mofetil) [27]. Typical manage-
ment of ADEs considers dose reduction of the offending
drug or switching to another immunosuppressant medi-
cation. All these properties impair dose adjustments and
tight drug-level control of immunosuppressant medica-
tions. There is evidence that clinical pharmacists can con-
tribute to the vigilant supervision and management of
kidney transplant patients [9,29,30].
Evaluation of drug use on the nephrology ward shows that
in-hospital treatment is associated with a significant
increase in the number of prescribed drugs and pDDIs.
Poly-morbidity is frequent, and multiple medications are
almost always necessary to meet treatment goals. Our
study illustrates that poly-medication, which is almost
inevitable in nephrology patients, leads to an increasing
number of pDDIs. Other authors report similar findings
in other patient populations [31,32]. It must be noted that
the number of drugs administered to the patient during
the active in-hospital treatment period is even higher
compared to the number at admission or discharge due to
temporary therapeutic treatments, such as anti-infectives
or anticoagulation drugs. Reviewing drug-drug interac-BMC Clinical Pharmacology 2009, 9:15 http://www.biomedcentral.com/1472-6904/9/15
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tions at admission and discharge provides only a frac-
tional view of all pDDIs that by definition can never be
complete. According to a published study by Glintborg
and colleagues, the clinical relevance of computerised
screening of pDDIs, as done in our study, tends to be low
[33]. However, in daily practice, this tool proves to be use-
ful for gaining a quick overview and raising awareness of
potential medication-related events. Considering the sen-
sitivity of patients with renal impairment and drug-related
needs, especially for pDDIs leading to increased nephro-
toxicity or aggravation of kidney function, these interac-
tions must be intensely and carefully monitored.
Recognition, avoidance and management of drug-drug
interactions and medication reviews should be done vigi-
lantly [3] as these procedures also represent markers of
treatment quality.
This pilot study was retrospective and was primarily
designed to identify different areas with intervention
needs (e.g., RFs, TDM) and possibilities for improvement
of drug therapy-related aspects (e.g., management of
pDDIs, medication reviews). Evidence from the literature
shows that these tasks are already performed by clinical
pharmacists as a part of their clinical routine. However,
the extent of clinical pharmacists' involvement varies con-
siderably. We are aware that this pilot study itself does not
contribute to the overall evidence on clinical pharmacy
services. However, we hypothesise that clinical pharma-
cists could play an important part in improving treatment
quality, as there is evidence supporting the benefit of clin-
ical pharmacy services in this area [7-11]. Since the proc-
ess of delivering drug therapy to in-hospital patients is a
complex, time-consuming, multi-step and therefore error-
prone process, clinical pharmacy services could enforce
drug-therapy safety and address therapeutic needs that are
being insufficiently met by other health care professionals
in the care delivery process.
As with all studies, our current investigations had limita-
tions. The assessment was done by a single pharmacist
and included only patients from one internal nephrology
ward. Data from other wards were not available. There-
fore, the possibility of data extrapolation is limited.
Conclusion
Our pilot study identifies possibilities and needs for
improvements in the management of hypertension, dia-
betes and hyperlipidemia, which are three major RFs for
renal and/or CV disease. In the subgroup of TX patients,
tight control of immunosuppressant blood levels accord-
ing to the reference range could be optimised. Medication
regimens are complex, and the frequency of pDDIs
increased during in-hospital treatment. Detected pDDIs
were frequently associated with a potential aggravation of
already impaired kidney function. Clinical pharmacy serv-
ices could positively influence RF management, TDM and
the management of pDDIs. However, this hypothesis
must be confirmed in future research. Based on our study
findings, the impact of clinical pharmacy services on drug-
therapy related problems and RF management should be
addressed using a prospective study design in a nephrol-
ogy patient population and a kidney transplant popula-
tion, respectively.
Competing interests
The study was performed as part of a clinical pharmacy
project that was funded by Amgen. The authors declare
that there are no financial or other conflicts of interests
with respect to the contents of the article.
Authors' contributions
GS was responsible for the study design, data collection
and interpretation and preparation of the manuscript. SZ
was responsible for the study design, statistical analysis of
collected data and reviewing the manuscript. RLG was
responsible for study design, data interpretation and
reviewing the manuscript. All authors read and approved
the final manuscript.
Appendix
Medis® is an Austrian general drug information tool with
a pDDIs screening function. The data used originates from
Mikropharm - Arzneimittelinteraktionen provided by a
collaboration of the Bundesvereinigung Deutscher Apoth-
ekerverbände (ABDA), Österreichische Apothekerkam-
mer (ÖAK) and Schweizer Apothekerverein (SAV).
The four categories of relevance were:
Severe interaction: combination may be life threatening;
possibility of intoxication; permanent damage may be
induced.
Moderate interaction: combination may lead to therapeu-
tic difficulties and may even be harmful; close patient
monitoring is needed.
Minor interaction: interaction is to be taken into account
but normally causes no harm to the patient.
Unknown relevance: no proven clinical relevance of
described interaction.
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